Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11004663 | 0.80 | NAAA (0.41) | ALDH1A1MAPK1LMNA | |
| SCHEMBL766244 | 0.74 | LMNA (0.33) | CA12CA1CA2KMT2ALMNA | |
| SCHEMBL11629491 | 0.74 | TSHR (0.34) | — | |
| SCHEMBL28791286 | 0.69 | CHRNB2 (0.45) | CA12CA1CA2CA9CYP19A1 | |
| SCHEMBL4672705 | 0.69 | CHRNB2 (0.45) | CA12CA1CA2CA9CYP19A1 | |
| SCHEMBL27558414 | 0.68 | CA1 (0.41) | CA12CA1CA2CA9CYP19A1 | |
| SCHEMBL1869451 | 0.68 | CA1 (0.48) | CA12CA1CA2CA9CYP19A1 | |
| SCHEMBL351059 | 0.68 | CA1 (0.48) | CA12CA1CA2CA9CYP19A1 | |
| SCHEMBL7947102 | 0.67 | CA1 (0.43) | CA12CA1CA2CA9CYP19A1 | |
| SCHEMBL2691885 | 0.67 | CA12 (0.43) | CA12CA1CA2CA9CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7102019-B2 | Cosmetic and pharmaceutical preparations comprising ascorbic acid derivatives | BASF AKTIENGESELLSCHAFT (DE) | 2006-09-05 | — | — | US | disclosed |
| US-RE39072-E1 | 2-aminopropane-1,3-diol compounds, medicinal use thereof, and intermediates in synthesizing the same | MITSUBISHI PHARMA CORPORATION (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20020034527-A1 | Cosmetic and pharmaceutical preparations comprising ascorbic acid derivatives | STREICHER HARALD (DE) | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020034527-A1 | Cosmetic and pharmaceutical preparations comprising ascorbic acid derivatives | PROC, ALDH16A1, RCN1 | CA12 219/4885CA1 601/4885CA2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.